Evidence map›Paper›PMID 34557417›Full record

ArticleFrontiers in oncology2021

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.

Xuan Wei, Juanjuan Shi, Qianhan Lin, Xiaoxue Ma, Yingxin Pang, Hongluan Mao, Rui Li, Wei Lu, Yu Wang, Peishu Liu

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Xuan WeiDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Juanjuan ShiDepartment of Gynecology and Obstetrics, Affiliated Tengzhou Center People's Hospital of Jining Medical University, Tengzhou, China.
Qianhan LinDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Xiaoxue MaDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Yingxin PangDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Hongluan MaoDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Rui LiDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Wei LuDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Yu WangDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Peishu LiuDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.642229.].

Indexed as

ACLYAMPK-ROS pathwaycisplatin resistanceovarian cancerPI3K-AKT pathway

Identifiers

PMID34557417
PMCPMC8453349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.